Skip to main content
. Author manuscript; available in PMC: 2022 Jan 11.
Published in final edited form as: Pediatr Blood Cancer. 2020 Jan 23;67(5):e28098. doi: 10.1002/pbc.28098

TABLE 3.

Evaluation for supra-additivity

Disease Xenograft Normalized interaction term Total effect expected Interaction parameter estimate P R 2 Interpretation
Neuroblastoma NB-1643 0.26 28.56 7.32 <0.001 0.98 Supra-additive
Neuroblastoma NB-Ebc1 0.22 13.54 2.97 0.085 0.89 Additive
Neuroblastoma NB-SD 0.18 17.22 3.11 0.083 0.92 Additive
Osteosarcoma OS1 0.03 34.53 1.16 0.812 0.75 Additive
Osteosarcoma OS2 0.24 8.16 1.98 0.481 0.44 Additive
Osteosarcoma OS31 2.34 7.39 17.30 <0.001 0.94 Supra-additive
Osteosarcoma OS33 0.69 18.17 12.47 <0.001 0.95 Supra-additive
Wilms tumor KT-10 −0.19 47.35 −8.80 0.117 0.82 Additive
Wilms tumor KT-11 −0.06 32.31 −1.87 0.626 0.82 Additive
Wilms tumor KT-13 0.17 25.36 4.35 0.615 0.41 Additive